文献
J-GLOBAL ID:201702212969777085
整理番号:17A0981188 アデノシン三リン酸結合カセットサブファミリーCメンバー8遺伝子変異により生じる一時的な新生児糖尿病の幼児のスルホニルウレア治療
Sulfonylurea treatment in an infant with transient neonatal diabetes mellitus caused by an adenosine triphosphate binding cassette subfamily C member 8 gene mutation
- 1. Aguilar-Bryan, L, Bryan, J. Neonatal diabetes mellitus. Endocr Rev 2008;29: 265-91.
- 2. Greeley, SAW, Tucker, SE, Naylor, RN, Bell, GI, Philipson, LH. Neonatal diabetes mellitus: a model for personalized medicine. Trends Endocrinol Metab 2010;21: 464-72.
- 3. Suzuki, S, Koga, M, Amamiya, S, Nakao, A, Wada, K, Okuhara, K, et al. Glycated albumin but not HbA1c reflects glycaemic control in patients with neonatal diabetes mellitus. Diabetologia 2011;54: 2247-53.
- 4. Hattersley, A. Transferring patients with diabetes due to a Kir6.2 mutation from insulin to sulphonylureas in patients who are aged under 1 year. http://www.diabetesgenes.org/content/transferring-patients-diabetes-due-kir62-mutation-insulin-sulphonylureas.
- 5. Rafiq, M, Flanagan, SE, Patch, AM, Shields, BM, Ellard, S, Hattersley, AT, Neonatal Diabetes International Collaborative Group. Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations. Diabetes Care 2008;31: 204-9.
- 6. Hashimoto, Y, Dateki, S, Hirose, M, Satomura, K, Sawada, H, Mizuno, H, et al. Molecular and clinical features of KATP -channel neonatal diabetes mellitus in Japan. Pediatr Diabetes 2016; [Epub ahead of print].
- 7. Remedi, MS, Agapova, SE, Vyas, AK, Hruz, PW, Nichols, CG. Acute sulfonylurea therapy at disease onset can cause permanent remission of KATP-induced diabetes. Diabetes 2011;60: 2515-22.
- 8. Villareal, DT, Koster, JC, Robertson, H, Akrouh, A, Miyake, K, Bell, GI, et al. Kir6.2 variant E23K increases ATP-sensitive K+ channel activity and is associated with impaired insulin release and enhanced insulin sensitivity in adults with normal glucose tolerance. Diabetes 2009;58: 1869-78.
前のページに戻る